Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

AI summary

Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts. For retail investors scanning headlines, the question is rarely about valuation multiples (most of these companies ... Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways